Request Demo
Last update 08 May 2025
Human papillomavirus vaccine recombinant pentavalent (Merck)
Last update 08 May 2025
Overview
Basic Info
Drug Type Virus-like particle vaccine, Therapeutic vaccine |
Synonyms 5valent HPV L1 VLP vaccine Merck, Human papillomavirus (types 31 33 45 52 58) L1 viruslike particle vaccine Merck, Pentavalent HPV VLP vaccine Merck + [1] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Human papillomavirus vaccine recombinant pentavalent (Merck)EUCTR2007-003852-13-AT
A Randomized, Double-Blinded, Tolerability and ImmunogenicityStudy of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine (V504) Administered Concomitantlywith GARDASIL™ to 16- to 26-Year-Old Women
NCT00551187
A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women
100 Clinical Results associated with Human papillomavirus vaccine recombinant pentavalent (Merck)
Login to view more data
100 Translational Medicine associated with Human papillomavirus vaccine recombinant pentavalent (Merck)
Login to view more data
100 Patents (Medical) associated with Human papillomavirus vaccine recombinant pentavalent (Merck)
Login to view more data
100 Deals associated with Human papillomavirus vaccine recombinant pentavalent (Merck)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Human Papillomavirus Infection | Phase 2 | Sweden | - | |
| Human Papillomavirus Infection | Phase 2 | United States | - | |
| Human Papillomavirus Infection | Phase 2 | Austria | - | |
| Uterine Cervical Cancer | Phase 2 | United States | - | |
| Uterine Cervical Cancer | Phase 2 | Austria | - | |
| Uterine Cervical Cancer | Phase 2 | Sweden | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free